going places

Houston female-founded startup takes on national expansion

Work & Mother — with the help of CBRE Group Inc. — is gearing up for a national expansion. Photo courtesy of Work & Mother

Houston-based Work & Mother Services LLC is embarking on a nationwide expansion of its network of lactation suites.

Work & Mother already operates two locations in downtown Houston (The Jones on Main and Three Allen Center) and is preparing to open locations at Four Oaks Place in Houston and Eastlake at Tillery in Austin. Beyond that growth, the company aims to expand to metro areas like Dallas-Fort Worth, Chicago, Los Angeles, and New York City.

Work & Mother has tapped Abby Alford and Lucian Bukowski of commercial real estate services company CBRE Group Inc. to find space in expansion markets. Both of them work out of CBRE's office on Post Oak Boulevard.

Work & Mother's lactation suites feature private rooms, hospital-grade pumps, and refrigeration and storage options. As part of its service, the company offers a booking app and support resources, such as lactation consultants and career coaches, to working mothers who are breastfeeding their babies.

"Most employers have a legal obligation to provide a proper space for nursing mothers, but pumping at work has always been incredibly difficult, with in-office solutions and multipurpose wellness rooms often failing moms and contributing to high turnover rates around motherhood — many employers don't even realize they have a problem until it's too late," Abbey Donnell, founder and CEO of Work & Mother, says in a CBRE news release.

"We look forward to supporting more new mothers' return to work and providing the real estate services that office tenants and landlords need in a post-pandemic world to promote wellness, flexibility, and inclusion in the workplace," Donnell adds.

A Work & Mother suite is an amenity shared by tenants of an office building. The company says its suites help employers adhere to federal labor laws, reduce HR risks, and retain female employees.

"The pandemic has forced tenants and landlords alike to reimagine workplaces with a greater focus on employee experience in order to recruit and retain top talent," CBRE's Alford says.

Donnell, a Rice University alumna, started her company in 2017. She is a certified lactation counselor and a former advertising executive.

Earlier this year, Work & Mother raised an undisclosed amount of funding from The Artemis Fund, a Houston-based firm that supports women-led startups; the Texas HALO Fund, a Houston-based investment firm; and the Beam Angel Network, an Austin-based nonprofit that backs startups founded by women.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News